<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00623662</url>
  </required_header>
  <id_info>
    <org_study_id>GEN-07-075</org_study_id>
    <secondary_id>CIHR 183635</secondary_id>
    <nct_id>NCT00623662</nct_id>
  </id_info>
  <brief_title>Preoperative Glucose Infusion: a Novel Strategy to Improve Liver Function After Liver Resection</brief_title>
  <official_title>Metabolic Preconditioning Using Intravenous Dextrose: a Novel Strategy to Improve Hepatic Function After Liver Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University Health Centre/Research Institute of the McGill University Health Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McGill University Health Centre/Research Institute of the McGill University Health Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the study is to determine whether intravenous glucose administration before liver&#xD;
      resection preserves hepatic glycogen resulting in improved hepatic metabolic function after&#xD;
      the operation.&#xD;
&#xD;
      We further investigate whether the benefit of avoiding preoperative fasting is more&#xD;
      pronounced in patients undergoing more extensive liver resection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background. With a reported incidence of up to 70%, liver failure is the most frequent&#xD;
      complication necessitating intensive care and prolonging hospital stay. Animal studies&#xD;
      suggest that the glycogen content of the liver is a key regulator of liver function and that&#xD;
      glycogen depletion, a mandatory consequence of preoperative fasting, is associated with poor&#xD;
      clinical outcome.&#xD;
&#xD;
      The results of a pilot study demonstrate that metabolic preconditioning, i.e. the avoidance&#xD;
      of preoperative fasting by intravenous administration of dextrose preserves hepatic glycogen&#xD;
      and prevents hepatic dysfunction after liver resection. Liver function in this protocol was&#xD;
      assessed by a score originally proposed by Schindl including serum concentrations of total&#xD;
      bilirubin and lactate, prothrombin time and degree of encephalopathy. Due to alterations&#xD;
      induced by anesthesia and surgery, e.g. blood loss necessitating transfusion, hypothermia,&#xD;
      inflammatory responses and use of drugs with impact on hepatobiliary metabolism, liver&#xD;
      function scores do not necessarily reflect functional integrity and metabolic capacity of the&#xD;
      liver. In contrast, measuring the production of proteins that are exclusively synthetized by&#xD;
      hepatocytes such as albumin allows a more specific and quantitative assessment of hepatic&#xD;
      performance under perioperative conditions.&#xD;
&#xD;
      Hypothesis. We propose a randomized double-blinded study to test the hypothesis that, in&#xD;
      patients scheduled for resection of liver cancer, metabolic preconditioning with intravenous&#xD;
      dextrose preserves hepatic glycogen resulting in improved hepatic metabolic function&#xD;
      postoperatively. We further hypothesize that the benefit of avoiding preoperative fasting is&#xD;
      more pronounced in patients undergoing more extensive liver resection. Hepatic synthetic&#xD;
      capacity will be assessed by measuring albumin synthesis using a stable isotope tracer&#xD;
      technique.&#xD;
&#xD;
      Research plan. In order to test the validity of our assumptions, we will perform studies in&#xD;
      patients scheduled for minor (study I; one or two liver segments, n=30) or major (study II;&#xD;
      three or more liver segments, n=20) liver resection. In a double blinded fashion patients&#xD;
      will be randomly assigned to receive either intravenous dextrose at 2 mg/kg/min or saline&#xD;
      from 15:00 on the day before the operation until surgical skin incision. Metabolic processes&#xD;
      at the organ level (liver, muscle), i.e. fractional synthesis rates of albumin, hepatic acute&#xD;
      phase proteins (transthyretin (=prealbumin), fibrinogen, total plasma proteins) and muscle&#xD;
      protein will be determined one day before and one day after the operation using&#xD;
      primed-continuous infusions of L-[2H5]phenylalanine. Stable isotopes (L-[1-13C]leucine,&#xD;
      [6,6-2H2]glucose) will be applied to assess dynamic changes in whole body protein and glucose&#xD;
      metabolism before and after surgery, i.e. protein breakdown, amino acid oxidation, protein&#xD;
      synthesis, glucose production and glucose uptake.&#xD;
&#xD;
      Significance. The demonstration that the preconditioning with dextrose preserves metabolic&#xD;
      performance of the liver would have important implications for the clinical management of&#xD;
      surgical patients with liver cancer. If preoperative dextrose administration attenuates&#xD;
      hepatic dysfunction after liver resection, it will provide these patients with a readily&#xD;
      available, safe and inexpensive therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2008</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of albumin synthesis</measure>
    <time_frame>One day before and one day after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transthyretin synthesis, fibrinogen synthesis, whole body glucose and protein kinetics</measure>
    <time_frame>One day before and one day after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hepatic Insufficiency</condition>
  <condition>Liver Failure</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glucose infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Preoperative glucose infusion</intervention_name>
    <description>Glucose infusion from 15:00 on the day before the operation until beginning of surgery.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Preoperative normal saline infusion</intervention_name>
    <description>Normal saline infusion from 15:00 on the day before surgery until beginning of the operation.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  American Society of Anesthesiologists class â‰¤3&#xD;
&#xD;
          -  liver resection (one or more liver segments) for primary or secondary malignancy&#xD;
&#xD;
          -  ability to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  signs of severe malnutrition or obesity: body mass index (BMI) &lt;20 or &gt;30 kg.m-2, more&#xD;
             than 10% involuntary body weight loss over the preceding six months, serum albumin &lt;35&#xD;
             g.L-1&#xD;
&#xD;
          -  chronic viral liver disease&#xD;
&#xD;
          -  diabetes mellitus&#xD;
&#xD;
          -  significant cardiorespiratory, renal and neurological disease&#xD;
&#xD;
          -  musculoskeletal or neuromuscular disease&#xD;
&#xD;
          -  severe anemia (hemoglobin &lt;10 g.dL-1)&#xD;
&#xD;
          -  history of severe sciatica or back surgery or other conditions which contraindicate&#xD;
             the use of an epidural catheter&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralph Lattermann, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anaesthesia, McGill University Health Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ralph Lattermann, MD PhD</last_name>
    <phone>514-934-1934</phone>
    <phone_ext>35802</phone_ext>
    <email>ralph.lattermann@muhc.mcgill.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas Schricker, MD PhD</last_name>
    <phone>514-934-1934</phone>
    <phone_ext>36057</phone_ext>
    <email>thomas.schricker@mcgill.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Victoria Hospital, McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralph Lattermann, MD PhD</last_name>
      <phone>514-934-1934</phone>
      <phone_ext>35802</phone_ext>
      <email>ralph.lattermann@muhc.mcgill.ca</email>
    </contact>
    <contact_backup>
      <last_name>Thomas Schricker, MD PhD</last_name>
      <phone>514-934-1934</phone>
      <phone_ext>36057</phone_ext>
      <email>thomas.schricker@mcgill.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Ralph Lattermann, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Schricker, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>George Carvalho, MD MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Metrakos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Linda Wykes, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mazen Hassanain, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>February 15, 2008</study_first_submitted>
  <study_first_submitted_qc>February 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2008</study_first_posted>
  <last_update_submitted>April 2, 2018</last_update_submitted>
  <last_update_submitted_qc>April 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McGill University Health Centre/Research Institute of the McGill University Health Centre</investigator_affiliation>
    <investigator_full_name>Ralph Lattermann</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Glucose infusion</keyword>
  <keyword>Liver function</keyword>
  <keyword>Liver resection</keyword>
  <keyword>Albumin synthesis</keyword>
  <keyword>Stable isotopes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

